WallStreetZen

NYSEMKT: BTX
Brooklyn ImmunoTherapeutics Inc Stock

$39.23-3.86 (-8.96%)
Updated May 6, 2021
BTX Price
$39.23
Fair Value Price
N/A
Market Cap
$58.12M
52 Week Low
$1.88
52 Week High
$80.67
P/E
-12.99x
P/B
68.29x
P/S
1.13x
PEG
N/A
Dividend Yield
0%
Revenue
$5.80M
Earnings
-$4.42M
Gross Margin
49.9%
Operating Margin
-73.84%
Profit Margin
-76.4%
Debt to Equity
3.4
Operating Cash Flow
-$4M
Beta
0.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BTX Overview

Zen Score

High
Medium
Low
3
Industry average

Reasons for this score

BTX is poor value based on its book value relative to its share price (68.29x), compared to the US market average (0.6x)
Valuation
BTX is poor value based on its book value relative to its share price (68.29x), compared to the US Biotechnology industry average (6.01x)
Valuation
BTX's cash and short-term investments ($777.00k) cannot cover BTX's cash burn for the next year ($4.16M), once increasing cash burn (153.36%) is accounted for
Financials

1 of 6

BTX News

Valuation

BTX fair value

Fair Value of BTX stock based on Discounted Cash Flow (DCF)
Price
$39.23
Fair Value
$2.96
Overvalued by
1,223.26%

BTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-12.99x
Industry
66.59x
Market
27.98x

BTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
68.29x
Industry
6.01x
Market
0.6x
BTX is poor value based on its book value relative to its share price (68.29x), compared to the US market average (0.6x)
Valuation
BTX is poor value based on its book value relative to its share price (68.29x), compared to the US Biotechnology industry average (6.01x)
Valuation

BTX's financial health

Profit margin

Revenue
$1.2M
Net Income
$307.0k
Profit Margin
25.4%
BTX's cash and short-term investments ($777.00k) cannot cover BTX's cash burn for the next year ($4.16M), once increasing cash burn (153.36%) is accounted for
Financials
BTX's profit margin has decreased (-66%) in the last year from (-10.4%) to (-76.4%)
Financials

Assets to liabilities

Assets
$3.7M
Liabilities
$2.9M
Debt to equity
2.46
BTX's short-term liabilities ($2.36M) exceed its short-term assets ($1.72M)
Financials
BTX's short-term assets ($1.72M) exceed its long-term liabilities ($534.00k)
Financials
BTX's debt has increased relative to shareholder equity (3.4), over the past 5 years ago (3.26)
Financials
BTX's debt to equity ratio (3.4) is considered high
Financials

Cash flow

Operating
-$614.0k
Investing
$1.2M
Financing
-$1.5M
BTX's cash and short-term investments ($777.00k) cannot cover BTX's cash burn ($4.16M) for 1 year
Financials

Brooklyn ImmunoTherapeutics Stock FAQ

What is Brooklyn ImmunoTherapeutics's quote symbol?

(NYSEMKT: BTX) Brooklyn ImmunoTherapeutics trades on the NYSEMKT under the ticker symbol BTX. Brooklyn ImmunoTherapeutics stock quotes can also be displayed as NYSEMKT: BTX.

What is the 52 week high and low for Brooklyn ImmunoTherapeutics (NYSEMKT: BTX)?

(NYSEMKT: BTX) Brooklyn ImmunoTherapeutics's 52-week high was $80.67, and its 52-week low was $1.88. It is currently -51.37% from its 52-week high and 1,986.7% from its 52-week low.

How much is Brooklyn ImmunoTherapeutics stock worth today?

(NYSEMKT: BTX) Brooklyn ImmunoTherapeutics currently has 1,481,433 outstanding shares. With Brooklyn ImmunoTherapeutics stock trading at $39.23 per share, the total value of Brooklyn ImmunoTherapeutics stock (market capitalization) is $58.12M.

Brooklyn ImmunoTherapeutics stock was originally listed at a price of $100.00 in Dec 31, 1997. If you had invested in Brooklyn ImmunoTherapeutics stock at $100.00, your return over the last 23 years would have been -60.77%, for an annualized return of -3.99%.

How much is Brooklyn ImmunoTherapeutics's stock price per share?

(NYSEMKT: BTX) Brooklyn ImmunoTherapeutics stock price per share is $39.23 today (as of May 6, 2021).

What is Brooklyn ImmunoTherapeutics's Market Cap?

(NYSEMKT: BTX) Brooklyn ImmunoTherapeutics's market cap is $58.12M, as of May 9, 2021.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Brooklyn ImmunoTherapeutics's market cap is calculated by multiplying BTX's current stock price of $39.23 by BTX's total outstanding shares of 1,481,433.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.